Product pulled from shelves in South Africa due to severe safety risks

The South African Health Products Regulatory Authority (SAHPRA) has issued a Class I Type A recall for all compounded Semaglutide, Tirzepatide, and combination products manufactured by iDexis (Pty) Ltd, also known as Sentra Pharmacy, in Pretoria. This urgent action follows a joint inspection conducted on May 11, 2026, which identified serious safety concerns regarding these medications.

The recall covers all batches of these specific compounded weight loss and diabetes medications currently in the market. Officials state that the move is necessary to protect patient wellbeing. Patients currently in possession of these pens or cartridges are advised to stop using them immediately. Pharmacies and healthcare professionals must also cease sales and distribution of these items.

Individuals who have received these products from the identified pharmacy should return them to their healthcare provider or the point of purchase for reimbursement. iDexis (Pty) Ltd has been tasked with arranging the collection of all affected stock. The regulatory body warns that because distribution occurred prior to the inspection, patients should check their medications against the provided list of affected batches immediately.

Healthcare workers and the public are encouraged to report any adverse side effects linked to these products via the Med Safety App. For direct assistance or inquiries regarding the recall process, contact the facility directly at +27 12 804 455. Maintaining awareness of medication safety standards remains critical, and authorities are managing the retrieval of these products to mitigate further health risks to the public.